Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

Published:2018-10-05 Issue:2 Volume:25 Page:410-420
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Battat Robert¹,Dulai Parambir S¹,Vande Casteele Niels¹,Evans Elisabeth¹,Hester Kelly D²,Webster Edvelyn²,Jain Anjali²,Proudfoot James A³,Mairalles Ara¹,Neill Jennifer¹,Singh Siddharth¹,Chang John T¹,Rivera-Nieves Jesus¹,Sandborn William J¹,Boland Brigid S¹

Affiliation:

1. Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, University of California, San Diego, La Jolla, California

2. Prometheus Laboratories Inc., San Diego, California

3. Clinical and Translational Research Institute, University of California, San Diego, La Jolla, California

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/25/2/410/27470932/izy307.pdf

Reference42 articles.

1. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases;Soler;J Pharmacol Exp Ther,2009

2. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

3. Vedolizumab as induction and maintenance therapy for Crohn’s disease;Sandborn;N Engl J Med,2013

4. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed;Sands;Gastroenterology,2014

5. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis;Mosli;Inflamm Bowel Dis,2015

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients;Bioengineering;2024-07-12

2. Advancements in Targeted Therapies for the Management of Crohn’s Disease: A Comprehensive Review;Cureus;2024-06-05

3. Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease;Gut;2024-04-05

4. Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments;Bioengineering;2024-01-01

5. Today and tomorrow: the use of biomarkers in inflammatory bowel disease;Canadian IBD Today;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3